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Abstract 
 
The restimulation of an immune memory response by in vitro culture of blood cells with a 
specific antigen has been used as a way to gauge immunity to vaccines for decades. In this 
commentary we discuss a less appreciated application to support vaccine process development.  
We report that human whole blood from pre-primed subjects can generate a profound adjuvant-
modulated, antigen-specific response to several different vaccine formulations. The response is 
able to differentiate subtle changes in the quality of an immune memory response to vaccine 
formulations and can be used to select optimal conditions relating to a particular manufacture 
process step. Whilst questions relating to closeness to in vivo vaccination remain, the approach is 
another big step nearer to the more relevant human response. It has special importance for new 
adjuvant development, complementing other preclinical in vivo and in vitro approaches to 
considerably de-risk progression of novel vaccines prior to and through early clinical 
development. Broader implications of the approach are discussed.               
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Introduction 
An ability to restimulate and monitor a vaccine-specific immune response in vitro can provide 
valuable insight to how a vaccine might perform in vivo. The information may be particularly 
relevant to the longer-term memory T cell population that can be stimulated and monitored after 
several days of in vitro culture with antigen and which is the most likely target for boosting by 
vaccines. The cultured response is due to a heterogeneous population found in peripheral 
circulation, broadly referred to as central memory T cells (Tcm).1,2 The Tcm population plays an 
important role in reactive memory and differs from effector or effector memory cells (Tem) that 
perform an effector function immediately upon contact with the cognate antigen. The Tcm 
possess surface molecules that direct them to secondary lymphoid tissue to receive antigenic re-
stimulation to become effector T cells. The Tcm are long-lasting, respond upon stimulation by 
secreting key cytokines (such as IFNγ), and in this way are thought to be instrumental in enabling 
other cells to engage the pathogen and mount a protective immune response.3 The generation and 
maintenance of the longer-term memory cells is therefore central to vaccinology and for the 
rational design of vaccines.4  
During preclinical development, the stimulation of human cells has been shown to be a suitable 
strategy to predict vaccine performance. For example, previous studies have cultured the 
peripheral blood mononuclear cells (PBMCs) from individual subjects in a specialized culture 
(referred to as MIMIC) that can enact a ‘trial-in-a-tube’, with the immunogenicity readout used as 
a surrogate for a potential clinical response.5  
Another in vitro application is for the immunomonitoring of clinical trials, where the immune 
response, typically in peripheral blood samples, is analyzed exhaustively to determine immune 
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response profiles, predictive of function or efficacy. Such testing is especially important for ‘first-
in-human’ trials (Phase I) and adaptive trial designs.   
An equally important, but possibly less appreciated, role is when a vaccine candidate progresses 
from preclinical development, to bioprocess development and the manufacture of a product to 
support Phase I through to Phase III clinical trials. Here the vaccine candidate will be formulated, 
scaled-up and manufactured using a quality by design (QbD) methodology.6 During the 
specialized formulation development cycle, the physiochemical properties of several different 
vaccine formulations are configured in the context of quality attributes considered to be critical to 
safety and efficacy. The critical quality attributes (CQAs) must include an immunogenicity or 
potency readout, which is arguably, the most critical attribute driving formulation and process 
development. Typically, the immunogenicity of formulations is tested in animal models. 
However, this approach faces several drawbacks, the most notable being whether the response in 
an animal truly translates to human. It is also questionable whether an animal model has sufficient 
sensitivity to screen precision formulations.  
As a way to complement and leverage animal immunogenicity and other preclinical data such as 
MIMIC, as well as to eventually bridge to early clinical trial data, we have looked to include an in 
vitro culture that uses diluted fresh human whole blood (hWB). Unlike other PBMC-based 
technologies, the hWB approach is considerably easier to perform and better suited to a 
bioprocess development facility where many formulations and processes need to be evaluated 
quickly using a more streamlined readout.        
The application discussed herein is specific to a vaccine candidate intended to boost or modulate 
pre-existing immunity. A good example is the tuberculosis (TB) vaccine candidate H4-IC31 that 
will boost the response primed by a prior Bacillus Calmette-Guerin (BCG) vaccination.7 
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However, there are many other examples, especially for booster vaccines targeted to adolescence, 
adult and elderly populations, where there is intent to modulate pre-existing immunity. Some 
examples include vaccines against the Varicella Zoster (Shingles), Pertussis, Diphtheria and 
Tetanus. In this commentary, specific features of the hWB approach for vaccine formulation 
development are highlighted and discussed. 
 
An adjuvant-modulated antigen-specific response 
When the hWB approach was in early development, it was clear that many groups had performed 
the shorter 6-24 hr culture period to monitor both non-specific innate immune signals and specific 
effector cell responses. Indeed, several commercial companies now use hWB cultures as a 
diagnostic (e.g. the QuantiFERON technology), or to support specific questions for the 
pharmaceutical industry (e.g. the ProStorm Cytokine Release Assay by ProImmune). Although 
the short-term hWB culture has a clear role in vaccine formulation development, it is not 
discussed any further here.       
Another more important challenge, at least for vaccine development, is the ability of a candidate 
vaccine to elicit a longer-term antigen-specific immune memory response. Several groups have 
used diluted hWB over an extended 6-7 day culture period to monitor this activity..8,9 A key goal 
in bioprocess development is to combine an antigen with an adjuvant in an optimal formulation as 
a ‘single-vial’ presentation. It was apparent that few, if any, groups had considered the antigen-
adjuvant combination in the longer-term hWB culture. Early in development of the ‘single-vial’ 
formulation, an unexpected finding was the ability to stimulate a profound adjuvant-modulated, 
antigen-specific response..10,11 To our best knowledge, no other group had reported this 
phenomenon before. For a vaccine developer, an ability to imitate or at least simulate, an 
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anticipated clinical response in human cells has several translational benefits. Not least, it is a 
relatively simple way to evaluate a functionally relevant response to a complete formulation 
(antigen and adjuvant) in human cells. A general approach for screening formulations is outlined 
briefly below.    
Screening human volunteers 
To screen specific vaccine formulations, the first step is to identify subjects who have an antigen-
specific memory response in peripheral circulation. These subjects tend to generate a variable but 
consistent memory response, assumed to be driven by Tcm, over several months, possibly years.12 
To select which subject to use for a formulation screen, the diluted fresh hWB from 17 randomly 
recruited volunteers were stimulated with several different vaccine candidate antigens mixed with 
or without a control TLR4-Agonist adjuvant (TLR4-A). Cultures were established in 10 wells of a 
96 U-well microtiter plate and the interferon gamma (IFNγ) released in pooled supernatant was 
monitored 6-7 days later. A summary of the responses for all subjects is shown in Table 1. The 
results demonstrate that an adjuvant-modulated antigen-specific response to different antigens and 
in a large proportion of subjects can be readily detected. In many cases, the presence of the 
adjuvant was a prerequisite to detecting an antigen-specific response. It was also clear that some 
antigens stimulated a better response than others, possibly relating to higher precursor frequencies 
of memory cell populations in the peripheral blood. The TA (TB antigen H4) stimulated a 
particularly good response in the presence of the adjuvant. As expected, the live attenuated virus 
(LAV) vaccine on its own stimulated a substantial response; however; the response was also 
augmented in the presence of TLR4-A. Taken together, the data provides valuable knowledge on 
the overall quality of the memory population being stimulated in the presence of an adjuvant with 
different antigens.    
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Screening vaccine formulations 
Having identified subjects with a responsive memory population, one subject was selected to use 
in a specific vaccine formulation screen. For the example shown in Figure 1, subject S05 was 
chosen to evaluate formulations of TA, the TB antigen H4, but in this case, adjuvanted with 
IC31®, a TLR9 Agonist adjuvant.13 The formulations screened were produced by 3 different 
manufacture process conditions (MPC 1-3) (Figure 1). The diluted fresh hWB was dispensed as 
before into a 96 U-well microtiter plate, but using a total of 30 wells/formulation. For this multi-
well methodology, wells are not seen as replicates but rather as discrete individual cultures.14 A 
statistical difference between the responses by each formulation can be determined across all 
individual wells by the Mann Whitney U test. Thus, the assay unveiled differences in the 
manufacturing process, identifying MPC 3 as suboptimal. The use of multiple wells allows for the 
response to be assessed in terms of its overall quality. The variability of the response across 
different wells highlights an anticipated complexity in the phenotype of the memory response in 
human cells.15  
 
Quality of antigenic restimulation 
To date, banked PBMCs isolated from peripheral blood are the basis of most cell based assays.  
However, the immune system is a complex combination of innate and adaptive pathways that can 
discern signals external or internal to cells to initiate an appropriate response against infections. 
Also a broad range of cells types that possess differing receptors (such as TLRs) and soluble 
mediators is used. Therefore, frozen PBMCs that can offer an important degree of consistency, 
may not necessarily provide a complete picture of the physiological response, especially relevant 
to new adjuvants.  
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Herein, we show that the fresh hWB can stimulate a profound adjuvant-modulated antigen-
specific response in the longer-term culture.10 It is not clear why the adjuvant has such a profound 
effect on the in vitro antigen-specific response. The most likely explanation is that in addition to 
conventional PBMCs, a number of other cell types such as neutrophils and soluble factors are 
present in hWB and these may be required to generate optimal innate signals.16,17 An adjuvant 
may cooperate with such cells to modulate the antigen-specific memory response that emerges 
several days later. Cultures also use autologous plasma and the presence of autologous antibody 
may be needed to generate additional optimal antigen-specific signals.18 Finally, whilst we are 
confident that the effects in hWB are antigen-specific, we cannot rule out the possibility for 
bystander synergistic effects. If confirmed, such effects may be far reaching.19  
Although the response from a selected subject is relatively consistent it can vary considerably. 
These responses can be normalized by comparing directly to a reference formulation monitored 
concurrently, both within and between subjects. An expected variability in the response between 
subjects will be important to understand.   
The data may have implications for ways to optimally restimulate cultures in vitro. Vaccine 
induced T cell responses are typically monitored by restimulating PBMCs with soluble antigens 
and/or peptides. However, soluble antigen and peptide are known to be poorly immunogenic. 
Apart from ingested food antigens that are well tolerated, it is difficult to conceive a situation, in 
vivo where soluble protein and/or peptide alone can stimulate a longer-term memory T cell 
response in the absence of some kind of ‘danger signal’. It is for this reason that vaccine antigens 
are formulated as particulates or combined with suitable adjuvants to imitate infection.   
The hWB data suggest that like vaccines, soluble antigen and/or peptide may need to be presented 
in the context of an innate immunomodulating event to generate a more relevant and optimal 
Page 9 of 16 
response in vitro. It is also likely that responses generated in the absence of adjuvant (or innate 
signals) may be underestimated and appear with more varied phenotypes, analogous to an 
orchestral performance with no conductor. 
One potential gap in understanding innate signals and adjuvantation, is the potential role for Tem. 
These cells elicit an effector function immediately upon contact with antigen and may play a role, 
similar to an adjuvant, in alerting danger and in modulating the longer-term antigen-specific 
response. Studies have shown that Tem and Tcm correlate, but the correlation is lost over time..2,20 
More studies are required to clarify the role of effector cells either alone or in synergy with an 
adjuvant to stimulate a robust protective memory population.  
Whilst an IFNγ readout has been used throughout, detailed studies are currently underway to 
understand proteomic and phenotypic (mass cytometry) properties associated with the modulated 
vaccine response in hWB culture. Biomarkers or signatures of an adjuvant-specific memory 
response should hopefully link to clinical data and would be invaluable to monitor for the 
manufacture of a quality product. 
 
Concluding remarks 
It is accepted that the in vitro hWB culture may be some way from the actual events required to 
recall an immune response in vivo. Activation of specific cells at the injection site, drainage to the 
lymph node and subsequent activities cannot be readily replicated in vitro. Nevertheless, an ability 
to at least simulate an adjuvant-modulated response is a big step forward in allowing new 
adjuvanted vaccine formulations to be monitored closely in an autologous culture in the presence 
of all components of blood. The approach offers a new functionally relevant readout closely 
aligned to MIMIC and the principals of QbD, permitting, at least in early clinical phases, some 
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linkage to functionality and CQAs. The approach is also aligned closely with a commitment to 
implement a 3R’s strategy (replacement, reduction and refinement of the use of animal testing), 
fitting neatly between preclinical and clinical evaluations.  
In terms of ease of use, the diluted fresh human blood can be collected from a local health center 
and applied to pre-prepared plates in a matter of minutes. With minimal hands-on time, the hWB 
culture becomes readily amenable to automation. Thus, both the number of antigens and subjects 
screened can be substantially amplified. The ability to reveal antigen-specific responsive cells 
easily in this way may have several potential applications beyond screening formulations, 
possibly touching on the potential for personalized medicine.  
At least by Phase III, a streamlined in vitro potency assay, appropriate to a controlled (GMP) 
environment, needs to be developed. Ideally the potency test would leverage all studies, both 
clinical and pre-clinical. The readouts from hWB and MIMIC and any other in vitro approach 
should strongly support development to such an assay. Ultimately in vitro studies on human cells 
will help determine relevant critical quality attributes (CQAs) that can be applied throughout 
manufacture under QbD principals. Such approaches may also considerably de-risk progression 
prior to and throughout clinical development.   
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Table 1. Magnitude of the IFNγ response by different subjects to different antigens in the 
presence or absence of a TLR4-Agonist adjuvant (TLR4-A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FA = Flu antigen, TA = Tuberculosis antigen - H4, LAV = Live attenuated virus, PA = Pertussis 
Antigen, TLR4-A = TLR4-Agonist adjuvant 
The hWB cultures were stimulated with 1ug/ml of antigen (LAV was used at 1x105 PFU/ml) and 
the IFNγ released in supernatants was determined by standard ELISA 6 days later. 
The IFNγ (pg/ml) measured in supernatant is indicated as:  
<120  -   
120-500  + 
500-1000 ++ 
1000-1500 +++ 
>1500   ++++ 
* Subject was selected for an H4-IC31 formulation screen in Figure 
Subject 
FA 
 
 
 
FA+ 
TLR4-A 
TA 
 
 
 
TA+ 
TLR4-A 
LAV 
 
 
 
LAV+ 
TLR4-A 
PA 
 
 
 
PA+ 
TLR4-A 
TLR4-A 
S01 -  - -  + +  ++ -  - - 
S02 -  - -  - -  - -  - - 
S03 -  - -  + -  + -  - - 
S05* -  - -  + -  + -  - - 
S06 -  - -  - -  - -  - - 
S07 -  - -  - -  + -  - - 
S08 -  - -  + +  + -  - - 
S09 -  - -  - -  + -  - - 
S10 -  ++ +  ++ ++  +++ -  + - 
S11 +  ++ -  - ++++  ++++ -  + - 
S12 +  ++ -  ++ ++++  ++++ -  ++ + 
S13 -  ++ -  - ++++  ++++ -  - - 
S14 -  - -  - +  + -  - - 
S15 -  - -  - -  - -  - - 
S16 -  - -  + -  - -  + - 
S17 -  + +  ++++ +  + -  - - 
S18 -  + ++  +++ -  + -  - - 
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Legend. 
 
Figure1. A comparison of three vaccine manufacture process conditions. The diluted fresh 
hWB from subject S05 was cultured with 3 different H4:IC31 formulations (MPC 1-3) using 30 
wells/formulation in a standard 96 U-well microtiter plate. All supernatants were harvested after 
10 days culture as previously reported.10  The H4 (0.1 μg/ml) and IC31 (4.0 nmol KLK) alone 
controls used 10 wells each. The graph shows a scatter plot +/- SD of the IFNγ released by 
individual wells to highlight differences in the overall quality of the response to each formulation. 
The MPC 3 formulation yielded significantly lower levels of IFNγ than the MPC 2 formulation (p 
= 0.013) (Mann Whitney U test).   
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